| 1. |
Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol, 2015, 44(6): 479-486.
|
| 2. |
Wallace MC, Preen D, Jeffrey GP, et al. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol, 2015, 9(6): 765-779.
|
| 3. |
Ozer Etik D, Suna N, Boyacioglu AS. Management of hepatocellular carcinoma: prevention, surveillance, diagnosis, and staging. Exp Clin Transplant, 2017, 15(Suppl 2): 31-35.
|
| 4. |
Sangmala P, Chaikledkaew U, Tanwandee T, et al. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients. Asian Pac J Cancer Prev, 2014, 15(20): 8993-9004.
|
| 5. |
安天志, 高嵩, 靳勇, 等. 中國肝細胞癌經動脈化療栓塞治療(TACE)臨床實踐指南. 介入放射學雜志, 2018, 27(12): 1117-1126.
|
| 6. |
Eggert T, Greten TF. Current standard and future perspectives in non-surgical therapy for hepatocellular carcinoma. Digestion, 2017, 96(1): 1-4.
|
| 7. |
Kim JH, Sinn DH, Shin SW, et al. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clin Mol Hepatol, 2017, 23(1): 42-50.
|
| 8. |
Moschouris H, Kalokairinou-Motogna M, Vrakas S, et al. Imaging of intrahepatic progression of hepatocellular carcinoma post transarterial chemoembolization. A long-term, prospective evaluation of contrast-enhanced ultrasonography (CEUS). Med Ultrason, 2017, 19(2): 134-142.
|
| 9. |
Cho YZ, Park SY, Choi EH, et al. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study. Clin Mol Hepatol, 2015, 21(2): 165-174.
|
| 10. |
Zhong J, Su Z, Zhang Y, et al. Contrast-enhanced ultrasonography versus contrast-enhanced computed tomography for assessment of residual tumor from hepatocellular carcinoma treated with transarterial chemoembolization: a meta-analysis. J Ultrasound Med, 2018, 37(8): 1881-1890.
|
| 11. |
夏要友, 陸信, 王家平, 等. 超聲造影在評價TACE治療肝癌效果的臨床價值研究. 昆明醫科大學學報, 2013, 34(7): 44-46.
|
| 12. |
Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol, 2018, 211(5): 1026-1034.
|
| 13. |
Thaiss WM, Haberland U, Kaufmann S, et al. Dose optimization of perfusion-derived response assessment in hepatocellular carcinoma treated with transarterial chemoembolization: comparison of volume perfusion CT and iodine concentration. Acad Radiol, 2018, pii: S1076-6332(18): 30465-3.
|
| 14. |
Tamandl D, Waneck F, Sieghart W, et al. Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control. Eur J Radiol, 2017, 90: 73-80.
|
| 15. |
Kloth C, Thaiss WM, K?rgel R, et al. Evaluation of texture analysis parameter for response prediction in patients with hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization (DEB-TACE) using biphasic contrast-enhanced CT image data: correlation with liver perfusion CT. Acad Radiol, 2017, 24(11): 1352-1363.
|
| 16. |
Kaufmann S, Horger T, Oelker A, et al. Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation. Eur J Radiol, 2015, 84(12): 2548-2554.
|
| 17. |
Wang J, Shen JL. Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A retrospective study. Medicine (Baltimore), 2017, 96(52): e9236.
|
| 18. |
Liu QY, He CD, Zhou Y, et al. Application of gemstone spectral imaging for efficacy evaluation in hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol, 2016, 22(11): 3242-3251.
|
| 19. |
江奇琦, 曹玉坤, 吳愛蘭, 等. 能譜CT多參數成像在肝癌TACE治療后隨訪中的初步研究. 臨床放射學雜志, 2018, 37(3): 518-523.
|
| 20. |
項昆, 趙鶴亮, 鄭昌英, 等. 16排螺旋CT和MRI對原發性肝癌TACE術后病灶的療效判斷價值對比. 實用癌癥雜志, 2014, 29(10): 1315-1317.
|
| 21. |
郭永建, 黃文藪, 周斌, 等. TACE聯合CT引導下射頻消融治療特殊部位小肝癌. 中華醫學雜志, 2013, 93(33): 2627-2630.
|
| 22. |
Wu LF, Rao SX, Xu PJ, et al. Pre-TACE kurtosis of ADCtotal derived from histogram analysis for diffusion-weighted imaging is the best independent predictor of prognosis in hepatocellular carcinoma. Eur Radiol, 2019, 29(1): 213-223.
|
| 23. |
張薇薇, 宋彬, 黃子星, 等. 術前表觀擴散系數預測肝癌行TACE后近期療效的價值. 中國普外基礎與臨床雜志, 2015, 22(9): 1133-1136.
|
| 24. |
Wu XM, Wang JF, Ji JS, et al. Evaluation of efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma using magnetic resonance diffusion-weighted imaging. Onco Targets Ther, 2017, 10: 1637-1643.
|
| 25. |
Chen X, Xiao E, Shu D, et al. Evaluating the therapeutic effect of hepatocellular carcinoma treated with transcatheter arterial chemoembolization by magnetic resonance perfusion imaging. Eur J Gastroenterol Hepatol, 2014, 26(1): 109-113.
|
| 26. |
Liang PC, Ch'ang HJ, Hsu C, et al. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. Hepatol Int, 2015, 9(2): 258-268.
|
| 27. |
Hsu HY, Yu MC, Lee CW, et al. RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma. BMC Cancer, 2017, 17(1): 742.
|
| 28. |
Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, et al. Prediction of post-TACE necrosis of hepatocellular carcinoma using volumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol, 2018, 28(7): 3032-3040.
|
| 29. |
Park S, Kim TS, Kang SH, et al. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization. Medicine (Baltimore), 2018, 97(37): e12311.
|
| 30. |
Ma W, Jia J, Wang S, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics, 2014, 4(7): 736-744.
|
| 31. |
Kim SH, Won KS, Choi BW, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging, 2012, 46(2): 102-110.
|
| 32. |
彭遼河, 胡曉燕, 李杰, 等. 18F-FDG PET/CT顯像在肝細胞癌TACE術后殘留或復發病灶檢出中的應用價值. 介入放射學雜志, 2012, 21(8): 636-640.
|
| 33. |
張韻, 黃子星, 宋彬. 肝細胞癌生物免疫治療的影像學評價現狀. 中國普外基礎與臨床雜志, 2018, 25(7): 867-872.
|
| 34. |
李天然. 肝細胞癌PET/CT研究進展. 胃腸病學和肝病學雜志, 2017, 26(11): 1201-1205.
|
| 35. |
柳昂, 許偉, 徐浩, 等. 三維-數字減影血管造影技術在肝動脈化學治療栓塞術中的應用價值探討. 中華肝臟病雜志, 2018, 26(6): 436-440.
|
| 36. |
Ladd LM, Tirkes T, Tann M, et al. Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma. Clin Mol Hepatol, 2016, 22(4): 450-457.
|